<DOC>
	<DOCNO>NCT00505791</DOCNO>
	<brief_summary>Heart failure ( HF ) disease cause reduced heart muscle function . Reduced heart muscle function occur consequence reduce pump activity weak heart muscle stiff heart muscle . This study look effectiveness Natrecor ( nesiritide ) patient require hospitalization due worsen heart failure result stiff thicken heart muscle . Natrecor man-made version protein body make approve treatment patient require hospital admission heart failure shortness breath rest minimal activity . Natrecor show low pressure heart decrease congestion lung . This study do see addition Natrecor standard medical therapy HF improve symptom faster completely give standard treatment CHF .</brief_summary>
	<brief_title>Double Blind Randomized Placebo Controlled Trial Natrecor Acute Decompensated Heart Failure With Normal EF</brief_title>
	<detailed_description>Despite increase number patient hospitalize decompensated heart failure presence normal ejection fraction , little clinical trial data guide clinicians acute management . Since number patient hospitalize decompensated heart failure presence normal ejection fraction ( &gt; 50 % ) increasing , imperative develop effective therapy support clinical evidence randomize clinical trial . The purpose study evaluate utility natriuretic peptide specific management patient . Loop diuretic ( Furosemide ) powerful diuretic agent use first-line therapy volume overload patient low ejection fraction heart failure . Despite widespread use , cause severe electrolyte volume abnormality contribute increased morbidity mortality . These adverse effect exacerbate even heart failure patient normal ejection fraction since patient usually older , bad renal function susceptible volume depletion effect . The FDA approve Natrecor Acute Decompensated Heart Failure differ low ejection fraction normal ejection fraction heart failure . Given however , low number patient normal ejection fraction heart failure clinical trial paucity outcome data patient , propose specifically study . Brief Description Experimental Approach : Patients present emergency room diagnose acute decompensated heart failure require administration intravenous diuretic find normal contractile function eligible participation study . Patients must pulmonary congestion document admit chest X-ray clinical evidence volume overload rales edema physical examination time randomization . Patients receive least one dose IV Furosemide either in-route emergency room presentation emergency room . An echocardiogram obtain presentation emergency room document normal ( &gt; 50 % ) leave ventricular ejection fraction . Patients randomize Natrecor placebo addition standard medical therapy . Study drug administer 24 hour . Study drug initiate 2-µg/kg loading bolus follow .01-µg/kg/min infusion . This may increase rate .005-µg/kg/min . every 3 hour maximum dose .03-µg/kg/min . Any increase infusion rate precede 1-µg/kg bolus increase infusion rate permit patient systolic blood pressure &gt; 100 mmHg . IV Nitroglycerin IV Milrinone prohibit within 2 hour prior initiate study drug infusion three hour completion study drug infusion . All intravenous vasoactive medication include IV inotropes avoid within 2 hour prior initiate study drug infusion three hour start study drug infusion . Oral ACE inhibitor avoid 2 hour prior initiate study drug infusion 30 minute start study drug avoid potential hypotension . Concomitant 'standard care medication ' include diuretic ( IV PO ) , ACE inhibitor , Aldactone , Digoxin etc . leave investigator discretion administer hospital stay indicate . The primary endpoint study absolute reduction brain natriuretic peptide ( BNP ) level three hour discontinuation study drug . BNP elevate acute decompensated heart failure utility outcome , severity prognosis patient ADHF . Secondary endpoint include : cause in-hospital mortality , physician patient global score 24 hour , twenty-four hour urine output start study drug infusion , weight change 24 hour start study drug infusion , number patient K &lt; 3.5meq 24 hour , change creatinine 24 hour start study drug discharge 3 day , BNP level baseline , 3 hour discontinuation study drug discharge 3 day , total diuretic dose IV PO Lasix 48 hour 72 hour randomization discharge , change diastolic index measure transthoracic echocardiography 24 hour start study drug 30 day post-randomization cause mortality .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Pulmonary Edema</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Patients great 18 year age Admission ED congestive heart failure require IV diuretic hospitalization Chest Xray evidence pulmonary congestion ( pleural effusion suffice ) . Physical evidence volume overload i.e . rale edema time randomization . Normal leave ventricular ejection fraction ( EF &gt; 50 % ) echocardiography presentation ER . Patients must able provide inform consent . Acute coronary syndrome evidence active ischemia evident acute ST segment T wave change initial cardiac enzyme demonstrate myocardial necrosis require IV nitroglycerin treatment . Hemodynamically unstable patient require invasive monitoring mechanical ventilation . Cardiogenic shock , volume depletion , clinical condition would contraindicate administration IV diuretic , ACE inhibitor , IV agent potent vasodilating property . Systolic blood pressure &gt; 220mmHg diastolic blood pressure &gt; 110mHg . Systolic blood pressure consistently &lt; 90 mmHg . Tachyarrhythmia ( HR &gt; 120 ) . Bradyarrythmia ( HR &lt; 50 ) . Myocarditis . Hypertrophic obstructive cardiomyopathy . Restrictive infiltrative cardiomyopathy include amyloid sarcoid . Constrictive cardiomyopathy . Primary right side heart failure severe pulmonary hypertension ( pulmonary artery pressure &gt; 60mmHg ) . Significant aortic mitral valve stenosis ( Aortic Valve Area &lt; 1.0cm2 , Mitral Valve Area &lt; 1.5 cm2 ) . Aortic mitral insufficiency ≥ 3+ . Malfunctioning artificial valve . Uncorrected congenital heart disease . Concomitant administration IV Dobutamine , IV vasoactive medication 2 hour start study drug 3 hour start study drug ; Administration IV Nitroglycerin IV Milrinone . Concomitant administration oral ACE inhibitor medication 2 hour start study drug 30 minute start study drug . Severe COPD/Asthma assess clinical criterion , prior PFT 's patient require chronic oral steroid treatment . Other significant pulmonary disease cause significant SOB/DOE i.e . pneumoconiosis etc . Patients creatinine &gt; 3.0 mg/dl . Patients serum potassium level &lt; 3.5 , &gt; 5.5 mmol/l . Anemia Hob &lt; 9 g/dl . Acute neurological event . Known allergic reaction contraindication Natrecor furosemide . Pregnancy suspect pregnancy . Patients history ETOH abuse illicit drug abuse . Patients active liver , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system medical condition disease opinion investigator may adversely effect safety efficacy study drug lifespan patient . Therapy investigational drug . Unwillingness inability comply study requirement include 30day followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute decompensated heart failure</keyword>
	<keyword>Normal leave ventricular ejection fraction</keyword>
	<keyword>Vasodilator therapy</keyword>
</DOC>